Cornelis Melief

Cornelis Melief developed the synthetic long peptide vaccine platform that has become one of the most successful approaches to therapeutic cancer vaccination, demonstrating durable clinical responses in HPV-associated cancers. His work on understanding how long peptides are processed and presented by professional antigen-presenting cells established the immunological rationale for this vaccine format over traditional short peptide approaches. His ISA101 HPV vaccine in combination with checkpoint inhibitors has shown promising clinical activity in cervical and head-and-neck cancers.